Cardiovascular disease drug discovery demands precision, human relevance, and translational insight to overcome high attrition rates and safety challenges. Evotec’s integrated approach combines deep disease biology expertise with advanced human-based platforms, including iPSC-derived cardiac models, multiomics-enabled Heart Atlas, and predictive cardiotoxicity screening. By leveraging AI-powered analytics and harmonized clinical datasets, researchers can identify disease-relevant targets, validate mechanisms of action, and de-risk programs early. This end-to-end flexibility—from stand-alone solutions to fully integrated partnerships—empowers scientists and decision makers to accelerate discovery with confidence and scale.